Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel SA : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/19/2018 | 09:15am EST

The company will report its earnings for FY 2017 on 03/22/2018. Generally, the company reports earnings worse than estimates. In recent months, the 3 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at -0.11 EUR for 2017 (- 90.2% from 2016). A summary of annual publications and estimates is available below.

Annual results2014201520162017 (e)2018 (e)
Sales
Million €
Released
Forecast
Spread


0,06
1,00
-94%
0,07
0,50
-86%

22,0

15,7
Operating income (EBITDA)
Million €
Released
Forecast
Spread


-11,7
-7,00
-67%
-24,3
-19,8
-23%

-1,00

-16,7
Operating profit (EBIT)
Million €
Released
Forecast
Spread
-6,90

-11,7
-12,5
6,2%
-24,3
-19,8
-22%

-1,60

-10,8
Pre-Tax Profit (EBT)
Million €
Released
Forecast
Spread

-21,0
-12,2
-13,0
5,8%
-24,5
-17,7
-38%

-1,73

-10,7
Net income
Million €
Released
Forecast
Spread
-14,1

-12,2
-13,5
9,3%
-24,5
-20,1
-22%

-2,73

-10,7
EPS
 €
Released
Forecast
Spread


-0,68
-0,67
-1,5%
-1,16
-0,89
-31%

-0,11

-0,49
Announcement Date04/30/201504/01/201604/03/2017
Stocks mentioned in the article
ChangeLast1st jan.
POXEL 0.81% 7.5 Real-time Quote.46.17%
THOMSON REUTERS CORPORATION 1.22% 93.88 Delayed Quote.40.71%

© MarketScreener.com 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
12/02POXEL : Announces Updates to its Management Team
AQ
11/27POXEL : Announces Positive Topline Results for Imeglimin Phase 3 Trial for the T..
AQ
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/30POXEL : Half-year report
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
More news
Financials (EUR)
Sales 2019 35,0 M
EBIT 2019 -19,8 M
Net income 2019 -20,0 M
Finance 2019 25,3 M
Yield 2019 -
P/E ratio 2019 -9,50x
P/E ratio 2020 -5,33x
EV / Sales2019 4,77x
EV / Sales2020 7,26x
Capitalization 192 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,44  €
Spread / Highest target 128%
Spread / Average Target 103%
Spread / Lowest Target 84,1%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL46.17%213
GILEAD SCIENCES5.40%83 411
VERTEX PHARMACEUTICALS34.61%57 362
REGENERON PHARMACEUTICALS-1.38%40 268
WUXI APPTEC CO., LTD.71.04%21 133
GENMAB51.29%15 619